CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Observational (registry)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug117 Bevacizumab Injection Wiki 0.71

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials

1 International COVID19 Clinical Evaluation Registry: HOPECOVID19. (Health Outcome Predictive Evaluation for COVID19)

The investigators propose to select all COVID 19 patients attended in any health center (with in hospital beds), who have been discharged or have died at the time of the evaluation. The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers). As secondary objectives, the analysis of the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed.

NCT04334291 COVID 19 Combination Product: Observational (registry)

Primary Outcomes

Description: All cause

Measure: Death

Time: through study completion, an average of 1 month

Secondary Outcomes

Description: Days

Measure: In hospital stay.

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Heart failure

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Renal failure

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Respiratory Insufficiency.

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Upper respiratory tract involvement

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Pneumonia

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Sepsis

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Systemic inflammatory response Syndrome.

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Clinically relevant bleeding

Time: through study completion, an average of 1 month

Description: According the attending physician.

Measure: Other complications.

Time: through study completion, an average of 1 month

No related HPO nodes (Using clinical trials)